...
首页> 外文期刊>Canadian journal of anesthesia: Journal canadien d'anesthesie >Conscious sedation for awake fibreoptic intubation: A review of the literature
【24h】

Conscious sedation for awake fibreoptic intubation: A review of the literature

机译:清醒性纤维化气管插管镇静:文献综述

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose: Awake fibreoptic intubation (AFOI) is the gold standard of management of the predicted difficult airway. Sedation is frequently used to make the process more tolerable to patients. It is not always easy to strike a balance between patient comfort and good intubating conditions on the one hand and maintaining ventilation and a patent airway on the other. In the last 30 years, many drugs and drug combinations have been described, but there is very little in the literature to help guide the practitioner to choose between them. The objective of this article is to discuss the evidence supporting the use of the agents described with regard to their efficacy, recommended doses and techniques, and limitations to their use for AFOI. Source: Publication databases were searched for articles published from 1996 to 2012 relating to sedation for AFOI. Principle findings: Benzodiazepines, propofol, opioids, alpha 2-adrenoceptor agonists, and ketamine are the main classes of drugs that have been described to facilitate AFOI. Drugs that are most suitable have a combination of both anxiolytic and analgesic properties. The ideal choice of drug may vary depending on the patient and the indication for AFOI. Conclusion: There is good evidence to support the use of two drugs in particular, remifentanil and dexmedetomidine. Each has certain unique characteristics that make them an attractive choice for an AFOI.
机译:目的:清醒光纤插管(AFOI)是预测困难气道管理的金标准。镇静常用于使患者对过程的耐受性更高。一方面要在患者舒适度和良好的插管条件之间保持平衡,另一方面要保持通气和呼吸道通畅,这并不总是那么容易。在过去的30年中,已经描述了许多药物和药物组合,但是在文献中很少有帮助指导从业者选择的药物。本文的目的是就其功效,推荐的剂量和技术以及其在AFOI中的使用限制方面,讨论支持所描述药物使用的证据。资料来源:在出版物数据库中搜索了1996年至2012年发表的有关AFOI镇静的文章。主要发现:苯二氮卓类,丙泊酚,阿片类药物,α2肾上腺素受体激动剂和氯胺酮已被描述为可促进AFOI的主要药物。最合适的药物兼具抗焦虑和止痛作用。药物的理想选择可能取决于患者和AFOI的适应症。结论:有充分的证据支持特别是瑞芬太尼和右美托咪定这两种药物的使用。每一种都有某些独特的特性,使其成为AFOI的诱人选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号